The funding milestone follows a period of significant growth for the company, which recently surpassed 2.5 million rings sold. Credit: T. Schneider/Shutterstock.

Finnish health technology company ŌURA has secured $200m in a Series D funding round, raising the company’s valuation to $5.2bn.

Fidelity Management & Research Company and DexCom led the funding round.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The capital injection will aid ŌURA to expand its product offerings and invest further in product, science, and healthcare innovation, including artificial intelligence.

Furthermore, the company will use the funding to advance expansion efforts globally and explore further acquisitions to expedite growth.

This funding milestone follows a period of significant growth for the company, which recently surpassed 2.5 million rings sold.

Additionally, ŌURA’s member base and revenue have more than doubled over the past year, the company said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This year, ŌURA expanded its retail presence globally with new partnerships, including Amazon and Target.

The company also grew its commercial business with expanded military partnerships, such as those with the Naval Health Research Center, the Air Force, and the Defense Innovation Unit.

Recently, the company also formed a partnership with Medicare Advantage provider Essence Healthcare and a strategic metabolic-health partnership with Dexcom.

The company recently introduced the next-generation Oura Ring 4, offering an unparalleled degree of accuracy, comfort, and personalisation through its breakthrough Smart Sensing technology.

Furthermore, ŌURA has expanded its product capabilities from its core Sleep and Activity pillars to include a broader range of health use cases, such as Heart Health, Stress & Resilience, and Women’s Health.

ŌURA CEO Tom Hale said: “As we continue to drive momentum and growth, we are bolstered by the additional support of these investors.

“We’ve made significant progress in advancing our mission to make health a daily practice and will use this funding to unlock new opportunities, with AI development at the center of our strategy. We know that ŌURA has the potential to change lives at scale, and we’re excited to continue leading the market in innovation while pursuing opportunities that extend beyond the ring.”

In November 2024, ŌURA announced an agreement to acquire Sparta Science, a company focusing on converting health and performance data into actionable intelligence.